Skip to main content
Logout
Boehringer Ingelheim Logo
Boehringer Ingelheim
Boehringer Ingelheim Logo
Boehringer Ingelheim
Boehringer Ingelheim Logo
Boehringer Ingelheim
  • Home
  • Therapeutic Areas
    Therapeutic Area

    At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our focus articulates who we are and what we strive for, how we work and what we want to achieve.

    • Therapeutic Areas
    • Metabolic
    • Cardiovascular
    • Respiratory
  • Products
    Products

    Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

    See all products
    • Products
    • See all products
      • Metabolic
      • View
      • Jardiance
      • Synjardy
      • Cardiovascular
      • View
      • Actilyse
      • Twynsta
      • Respiratory
      • View
      • OFEV
  • Resources
  • Contact us
  • Logout

    Boehringer Ingelheim

    logo_actilyse_za.png
    • Dosing
    • Mode of Action
    • Efficacy

    Stroke - Act Fast

    Effective in acute ischaemic stroke up to 4,5 hours after symptom onset

    Actylise-banner

    Stemi Dosage

    Actilyse Dosage & Administration: Myocardial Infarction

    Document ID: PC-ZA-102780 | Expiry Date: 07/29/2026

    Actilyse Dosage Guidelines for STEMI Treatment

    RELATED CONTENT

    1. Home
    2. Cardiovascular
    3. Actilyse
    4. Actilyse Dosage Guidelines for STEMI Treatment

    Sitemap

    • Therapeutic Area

      • Cardiovascular
      • Metabolic
      • Respiratory
    • Resources

      • Videos
      • Clinical Studies
    • Contact

    • Prescribing Information

      • Actilyse
      • Jardiance
      • OFEV
      • Synjardy
      • Twynsta

    Boehringer Ingelheim Logo
    BI
    • Sitemap
    • Privacy
    • Terms of use
    • Prescribing Information

    .

    To report any adverse events, please use the following email address: pv_local_south_africa@boehringer-ingelheim.com

     © 2010-2023 Boehringer Ingelheim International GmbH. All rights reserved. PC-ZA-102790